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Presence of endosome-disrupting multiple histidine function-
alities in the molecular architecture of cationic polymers,
such as polylysine, has previously been demonstrated to
significantly enhance their in vitro gene delivery efficiencies.
Towards harnessing improved transfection property through
covalent grafting of endosome-disrupting single histidine
functionality in the molecular structure of cationic lipids,
herein, we report on the design, the synthesis and the
transfection efficiency of two novel nonglycerol-based
histidylated cationic amphiphiles. We found that L-histidine-
(N,N-di-n-hexadecylamine)ethylamide (lipid 1) and L-histi-
dine-(N,N-di-n-hexadecylamine,-N-methyl)ethylamide (lipid
2) in combination with cholesterol gave efficient transfections
into various cell lines. The transfection efficiency of Chol/lipid
1 lipoplexes into HepG2 cells was two order of magnitude
higher than that of FuGENETM6 and DC-Chol lipoplexes,
whereas it was similar into A549, 293T7 and HeLa cells. A
better efficiency was obtained with Chol/lipid 2 lipoplexes
when using the cytosolic luciferase expression vector
(pT7Luc) under the control of the bacterial T7 promoter.
Membrane fusion activity measurements using fluorescence
resonance energy transfer (FRET) technique showed that
the histidine head-groups of Chol/lipid 1 liposomes mediated
membrane fusion in the pH range 5–7. In addition, the
transgene expression results using the T7Luc expression
vector convincingly support the endosome-disrupting role of
the presently described mono-histidylated cationic transfec-
tion lipids and the release of DNA into the cytosol. We
conclude that covalent grafting of a single histidine amino
acid residue to suitable twin-chain hydrophobic compounds
is able to impart remarkable transfection properties on the
resulting mono-histidylated cationic amphiphile, presumably
via the endosome-disrupting characteristics of the histidine
functionalities.
Gene Therapy (2003) 10, 1206–1215. doi:10.1038/
sj.gt.3301979
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Introduction
Gene therapy, because of its aim to eradicate causes
rather than symptoms of diseases, is believed by many to
be the therapy of the future. Recent completion of the
working draft of human genome has strengthened such
belief. However, spontaneous delivery and expression of
the supplemented correct copy of the malfunctioning
genes into cells is unlikely to be an efficient process due
to the unfavorable electrostatic interactions between
macromolecular DNA and biological cell surface (both
being negatively charged) and due to the nuclease
sensitiveness of nonprotected DNA. To develop an
efficient gene therapeutic approach, one must design
safe and efficient gene delivery reagents. These goals are
inseparable in a sense that any shortcomings in one will
adversely affect the success of the other. In other words,
realization of the full potential of gene therapy will
depend, in a major way, on the future development of
safe and efficient gene delivery reagents.
Transfection vectors commonly used in gene therapy
are mainly of two types: viral and nonviral. The
efficiencies of viral transfection vectors1 are, in general,
superior to their nonviral counterparts. However, serious
immunogenicity concerns associated with the use of viral
vectors2 combined with their limited insert-size and high
product cost are increasingly making the nonviral gene
delivery reagents the vectors of choice. Among the
existing arsenal of nonviral gene delivery reagents, the
distinct advantages associated with the use of cationic
liposomes include their low immunogenic response,
robust manufacture, ease in handling and preparation
techniques, and the ability to inject large lipid:DNA
complexes. Ever since Felgner et al3 reported their
pioneering development of cationic lipid-mediated gene
delivery protocol in 1987, many reports aimed at
developing more efficient cationic transfection lipids
have appeared in the literature.4–10 Recently, we haveReceived 5 September 2002; accepted 4 December 2002
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also developed efficient nonglycerol-based cationic
transfection lipids.11–15 In sharp contrast, details of
cationic lipid-mediated transfection pathways still re-
main elusive. According to our current understanding,
the intracellular pathways involved in lipoplex (lipid–
DNA complex)-mediated transfection include: (a) en-
docytotic cellular uptake of lipoplex; (b) the endosomal
release of DNA into the cytosol and (c) the transport of
DNA into the cell nucleus followed by its transcription
and expression.16–19
The weak efficiency of plasmid transfer into the
cytosol remains one of the major limiting factors to
achieve efficient transfection. For lipofection, the neutral
fusogenic colipid 1,2-dioleoyl-sn-glycero-3-phosphoetha-
nolamine (DOPE), in combination with a cationic lipid, is
usually used to favor the cytosolic delivery of plasmid.
In the area of cationic polymer-mediated gene delivery,
remarkable transfection efficiency was previously
achieved by one of our groups through covalent grafting
of endosome-disrupting multiple histidine functional-
ities in the molecular architecture of cationic polymer.20
Optimal conditions for transfection have been obtained
when polylysine was substituted with 7279 histidyl
residues corresponding to a polylysine substitution level
of 3875%.21 Based on these data, N-Ac-poly(L-histidine)-
graft-poly(L-lysine) comb-shaped polymer has also been
designed.22 More recently, Chen et al23,24 have succeeded
in demonstrating the enhanced transfection efficiencies
of cationic liposomes used in combination with copoly-
mers of histidine and lysine.
Herein, we report on the design, synthesis and
transfection efficiency of two novel histidylated cationic
amphiphiles (1 and 2, Schemes I and II) containing
a single endosome-disrupting histidine head-group. As
delineated below, membrane fusion activity measure-
ments using resonance energy transfer technique in the
pH range 5–7 support the view that the release of DNA
from the endosomally trapped lipoplexes to the cytosol is
likely to be mediated by the histidine head-groups of the
cationic amphiphiles. Cytosolic transgene expression in
293T7 cells using the pT7Luc plasmid encoding lucifer-
ase gene under the control of the bacterial T7 promotor
further supports this cytosolic release of DNA from
lipoplexes made of the present mono-histidylated catio-
nic lipids.
Results and discussion
Chemistry
We designed and synthesized two simple mono-histidy-
lated cationic lipids 1 and 2 using the precursor mixed
primary–tertiary amine II (Scheme 1) readily available in
one of our laboratories. The endosome-disrupting histi-
dine functionality in the head-group region of lipid 1 was
covalently grafted by conventional dicyclohexyl-carbo-
diimide (DCC) coupling of di-tetr-butyl-pyrocarbonate
(di-Boc)-protected histidine (IV) and the hydrophobic
mixed tertiary–primary amine (III) followed by acid
deprotection and chloride ion-exchange chromatography
of the resulting intermediate V as outlined in Scheme 1.
The mixed tertiary–primary amine III was prepared by
reacting N,N-di-hexadecylamine (I) with N-tert-butylox-
ycarbonyl protected 2-bromoethylamine in ethyl acetate
(EtoAc) in the presence of anhydrous potassium carbo-
nate followed by deprotection and neutralization of the
resulting intermediate II (Scheme 1).
Lipid 2 was synthesized by quaternizing the common
intermediate V with excess methyl iodide followed by
acid deprotection and chloride ion-exchange chromato-
graphy of the resulting quaternized intermediate VII
(Scheme 2).
Transfection efficiency
Toward addressing the comparative transfection proper-
ties of lipids 1 and 2 in nuclear and cytoplasmic
expression systems, both a conventionally used nuclear
expression plasmid pCMVLuc and a cytosolic expression
plasmid pT7Luc have been used in human embryonic
kidney 293-T7 cells. These cells stably express low levels
of T7 RNA polymerase, an enzyme necessary for the
cytoplasmic transcription of genes controlled by the
bacteriophage T7 RNA polymerase promoter. The use of
cytoplasmic expression systems with T7 RNA polymer-
ase capable of ensuing cytoplasmic expression of the
transfected genes has been demonstrated to be an elegant
way to avoid nuclear barrier of transfection pathways.25–29
Experiments conducted with lipid 1 using both
pCMVLuc and pT7Luc plasmids in 293T7 cell lines
revealed that the transfection efficiency was not sensitive
to either cholesterol-to-lipid 1 molar ratios (in the range
1:2–3:1) or to the lipid 1-to-DNA charge ratios (in the
range 3.5–1.3) (Figure 1). The observed lower transfection
efficiencies for pT7Luc compared to that for pCMVLuc
could result from the low level of the T7 RNA
polymerase present in 293T7 cells and/or the weak
strength of the promoter. Increasing the lipid-to-DNA
charge ratios significantly enhanced the transfection
efficiency with pCMVLuc at a constant cholesterol-to-
lipid 1 molar ratio of 2:1 (Figure 2a). The luciferase
expression was 10-fold higher at N/P¼1.75 than at N/
P¼1. However, the expression of pT7Luc was optimal
with the lipid-to-DNA charge ratio around N/P¼1
(Figure 2b). Above this ratio, no benefit was obtained:
the luciferase activity was lower at N/P¼1.75. An excess
of cationic charges is likely to increase interactions
between liposomes and DNA. In the case of the nuclear
gene expression system (pCMVLuc), it would prevent a
rapid dissociation of the lipoplexes inside the cell,
protecting DNA from degradation and thereby favoring
its nuclear delivery. Conversely, in the case of the
cytosolic gene expression system (pT7Luc), a high
lipoplexes stability could be a limiting factor. Therefore,
a decrease of the amount of cationic liposomes would
reduce the stability of lipoplexes, facilitating their
dissociation and the accessibility of the DNA to the
cytoplasmic expression machinery.
Cholesterol in combination with lipid 1 with a molar
ratio of 2:1 formed liposomes (Chol/lipid 1) with a size
of 78724 nm. Under the same conditions, the sizes of
commercially available liposomes such as Lipofectin,
LipofectAMINE, DOTAP and DC-Chol were found to be
68720, 77725, 51 and 170750 nm, respectively. The x
potential (the global charge) of Chol/lipid 1 was
3271.5 mV. This value was similar to that of Lipofectin
and LipofectAMINE but, higher than that of DC-Chol
(1671.5 mV) and lower than that of DOTAP (5572 mV).
When mixed with 5 mg of plasmid DNA, Chol/lipid 1
(2:1) formed lipoplexes with a size of 490720 nm and
exhibited a negative x potential of 2.5 mV. Electro-
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phoretic agarose gel analysis showed that all the DNA
was completely retarded under these conditions (data
not shown).
The transfection efficiency of the present lipoplexes
was compared with that of FuGENEt6 and DC-Chol/
DOPE, two widely used commercially available nonviral
transfection kits, in four different cultured cell lines
namely, A549, 293T7, HeLa and HepG2 (Figures 3 and 4).
The most impressive transfection efficiency was obtained
for HepG2 cells. The luciferase activity upon transfection
with Chol/lipid 1 lipoplexes was two order of magni-
tude higher than that obtained using FuGENEt6 and
DC-Chol/DOPE. The transfection efficiency of Chol/
lipid 1 lipoplexes into A549, 293T7 and HeLa cells was
similar to that obtained upon transfection with FuGEN-
Et6 and DC-Chol/DOPE.
Transfection data obtained with liposomes made with
lipid 1 indicated that they were more efficient than those
made with lipid 2. Representative comparative trans-
fection results in HepG2, HeLa and 293T7 cells are
summarized in Figure 5. At a cholesterol-to-lipid molar
ratio of 2:1, the transfection efficiency of Chol/lipid 2
was observed to be lower than that of Chol/lipid 1. With
HepG2 and HeLa cells, Chol/lipid 1 lipoplexes (at a
molar ratio of 2:1 and 1:1) exhibited a superior trans-
fection efficiency to Chol/lipid 2 across the varying
cholesterol-to-lipid 2 molar ratios of 2:1 to 1:2 (Figure 5a
and b). With 293T7 cells, the transfection efficiency of
Chol/lipid 2 (at a molar ratio of 1:2) was superior to
Chol/lipid 1 (at a molar ratio of 2:1) (Figure 5c). The
transfection efficiency of Chol/lipid 2 was significantly
higher than that of DOTAP, another widely used
commercially available simple cationic transfection lipid.
Interestingly, the transfection efficiency of Chol/lipid 2
(at a molar ratio of 1:2) using the cytoplasmic expression
plasmid (pT7Luc) was 10-fold higher than that of Chol/
lipid 1 across the varying cholesterol-to-lipid 1 molar
ratios of 2:1–1:2 (Figure 5d). Such better transfection
efficiency of Chol/lipid 2 in cytoplasmic expression
system may originate from an enhanced release of
the plasmid and/or its better accessibility by the T7
RNA polymerase. Clearly, further mechanistic investiga-
tions are needed to throw more light into the origin of
such differential relative transfection profile of Chol/
lipid 1 and Chol/lipid 2 in cytoplasmic and nuclear
expression systems. It is noticeable that the cellular
toxicity of Chol/lipid 2 was found to be very low (data
not shown).
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Scheme 1 Reagents: (i) Br CH2CH2NHBoc, EtoAc, 601, 36 h; (ii) TFA, DCM, 12 h; (iii) 1 N NaOH, DCM, 2 h; (iv) DCC, HOSu, DMF/DCM, 24 h;
(v) HCl in dioxane, 12 h; (vi) Amberlyst A-26 chloride ion-exchange resin.
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Membrane-disrupting capacity of histidylated cationic
liposomes
Toward addressing the membrane-disrupting capacity of
the presently described histidylated cationic liposomes
for endosomal membranes, we have exploited the widely
used fluorescence resonance energy transfer (FRET)
technique developed by Struck et al30 This technique
depends upon the interactions that occur between two
fluorophores when the emission band of one, the energy
donor, overlaps with the excitation band of the second,
the energy acceptor, because the two probes are in close
physical proximity. These conditions are satisfied within
a liposome made of both donor and acceptor fluorophore
lipids such as N-(7-nitro-2-oxa-1,3-diazol-4-yl)-1,2-dihex-
adecanoyl-sn-glycero-3-phosphoethanolamine (NBD-PE)
and Rhodamine Redt-x1,2-dihexadecanoyl-sn-glycero-3-
phosphoethanolamine (Rho-PE), respectively. In such
liposomes, the energy from a photon absorbed by the
energy donor, NBD-PE, is transferred to the energy
acceptor, Rho-PE, causing the latter to fluoresce as if it is
excited directly. Since the efficiency of FRET between two
such fluorophores is dependent upon their spatial
separation, any fusion event of such double-fluoro-
phore-containing liposome with a second liposome
devoid of any fluorophore decreases the efficiency of
resonance energy transfer. Thus, any decrease in FRET
efficiency provides evidence for membrane fusion.
Keeping in view the acidity (pH 5–6) of the lumen of
endosomes, membrane fusion measurements using
FRET technique were carried out in the pH range 5.0–
7.4 in the present investigation. When egg yolk phos-
phatidyl choline (PC)/NBD-PE/Rho-PE liposomes
containing both the fluorescent donor and acceptor
phospholipid analogs were mixed with Chol/lipid 1
(lipid molar ratio of 2:1 with no added fluorophore) at
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Figure 1 Transfection efficiency of Chol/lipid 1. 293T7 cells were
transfected with 2.5 mg of either pCMVLuc (a) or pT7Luc (b). The
luciferase activity was measured upon 24 h culture. N/P is the charge
ratio between the number of cationic charges of the liposomes (two
positive charges for lipid 1 at pH 7.4) and the negative charges of the
plasmid. The transfection values shown are average of three independent
experiments.
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pH 7.4, no significant loss of FRET efficiency was
observed, indicating that no fusion occurred (Figure 6).
However, when the fusion was induced at pH 5.0 or 6.0,
a significant decrease of FRET efficiency was observed.
The extent of the acid-induced fusion depended upon
the amount of histidylated liposomes added, and 50% of
FRET efficiency was obtained in the presence of about
0.1 mM lipid (Figure 6 inset). Similar results were
obtained by using liposomes made with PC, L-a-
phosphatidylethanolamine (PE), L-a-phosphatidyl-L-ser-
ine (PS) and cholesterol (PC/NBD-PE/Rho-PE/PE/PS/
cholesterol; 44%:5%:5%:16%:10%:20%), a lipid composi-
tion close to that of the plasma membrane (data not
shown). Presumably, the histidine head-group of lipid 1
destabilizes lipid bilayers in a slightly acidic medium
and thereby induces membrane fusion upon protonation
of the imidazole groups by increasing interactions
between lipid 1 and the membrane phospholipids. Given
the low acidity of endosomes, such enhanced decrease in
FRET efficiency at pH values 5 and 6 is consistent with
the endosome-fusion property of the presently described
mono-histidylated cationic transfection lipids. In addi-
tion, the transgene expression results summarized in
Figures 1b, 2b and 5d using the cytoplasmic expression
vector (pT7Luc) convincingly demonstrate the cytosolic
delivery of DNA from endosomes. Such cytosolic
delivery indirectly supports the endosome-disrupting
role of the presently described mono-histidylated catio-
nic transfection lipids.
Conclusion
In summary, we show that covalent grafting of a single
histidine amino acid residue to suitable twin-chain
hydrophobic compounds is sufficient to impart remark-
able transfection properties on the resulting mono-
histidylated cationic amphiphile presumably via the
endosome-disrupting characteristics of the histidine
functionalities. To date, reports on the use of mono-
histidylated cationic lipid for in vitro gene delivery are
few. The only other mono-histidylated cationic lipid that
we are aware of is a recent structure–activity report by
Heyes et al31 in which only two mono-histidylated
cationic compounds were included in a library of 61
cationic lipids with various amino acid head-groups and
varying chain length aliphatic hydrophobic anchors
connected via glycerol linkers. Thus, the endosome
fusion properties of the presently described lipids
indicate that undertaking of systematic structure–activity
investigation involving a series of mono-histidilyted
cationic lipids with varying anchor lengths and diverse
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Figure 2 Transfection efficiency of Chol/lipid 1 (lipid molar ratio of 2:1)
versus the liposome/DNA charge ratio. 293T7 cells were transfected with
2.5 mg of either pCMVLuc (a) or pT7Luc (b) complexed with various
amounts of liposomes. N/P is the charge ratio between the number of
cationic charges of the liposomes (two positive charges for lipid 1 at pH
7.4) and the negative charges of the plasmid. The luciferase activity was
measured upon 24 h culture. The transfection values shown are average of
three independent experiments.
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Figure 3 Transfection efficiency of Chol/lipid 1 into A549 and 293T7 cells.
The cells were transfected with 2.5 mg pCMVLuc complexed with Chol/
lipid 1 (lipid molar ratio of 2:1). The luciferase activity was measured upon
24 h culture. DC-Chol/DOPE was used at a lipid molar ratio of 3:2.
The transfection values shown are average of three independent
experiments.
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hydrophobic skeletons is likely to be rewarding. Toward
this end, work is under progress in our laboratories.
Materials and methods
Synthesis
N,N-di-n-hexadecylamine (I). A mixture of 8 g of n-
hexadecylamine (33.2 mmol), 10.2 g of n-hexadecyl bro-
mide (33.2 mmol) and 1.8 g of anhydrous potassium
carbonate (13.1 mmol) in 4 ml dimethyl sulfoxide was
kept under stirring for 12 h at 801C. The reaction mixture
was taken in 100 ml chloroform, washed with water
(3 100 ml), dried over anhydrous magnesium sulfate
and filtered. Chloroform was removed from the filtrate
on a rotary evaporator. Silica gel column chromato-
graphic purification of the resulting residue, using 60–
120 mesh silica gel size and 1–2% methanol in chloro-
form (v/v) as the eluent, afforded 3.5 g (23% yield) of the
intermediate secondary amine (Rf¼0.6 in 10% methanolic
chloroform, v/v, as the TLC developing solvent).
1H NMR (200 MHz, CDCl3): d/ppm¼0.9 [t, 6H, CH3-
(CH2)12-]; 1.2–1.3 [m, 52H, -(CH2)13-CH3]; 1.5 [m, 4H,
N(-CH2-CH2-)2]; 2.4 [t, 4H, N(CH2-CH2-)2].
N-[2-tert-butyloxycarbonylamino ethyl]-N,N-di-n-hexa-
decylamine (II). A mixture of 2.2 g (4.7 mmol) of N,N
di-n-hexadecylamine (I) and 1.1 g (5.2 mmol) of N-tert-
butyloxycarbonyl-2-bromoethylamine (prepared conven-
tionally by reacting 2-bromoethylamine hydrobromide
with di-tert-butyl pyrocarbonate in the presence of
triethylamine followed by usual work up) was refluxed
in EtoAc in the presence of anhydrous potassium
carbonate (1.4 g; 10 mmol) for 36 h. The reaction mixture
was taken in 100 ml chloroform, washed with water
(2 100 ml), dried over anhydrous magnesium sulfate
and filtered. Chloroform was removed from the filtrate
on a rotary evaporator. Silica gel column chromato-
graphic purification of the resulting residue (using 60–
120 mesh silica gel size and 0.5% methanol in chloro-
form, v/v, as the eluent) afforded 2 g (light yellow solid,
71% yield) of the title tertiary amine (Rf¼0.6 in 5%
methanolic chloroform, v/v, as the TLC developing
solvent).
1H NMR (200 MHz, CDCI3): d/ppm¼0.9 [t, 6H, CH3-
(CH2)13-]; 1.2–1.4 [m, 52H, -(CH2)13-CH3]; 1.5 [s, 9H, -O-
CO-C(CH3)3]; 2.4 [t, 4H, -N(CH2-(CH2-)13]; 2.5 [t, 2H, -
N(CH2-CH2-NHBoc]; 3.1 [m, 2H, N(CH2-CH2-NHBoc)];
4.9 [bm, 1H, NHBoc].
N-2-aminoethyl-N,N-di-n-hexadecylamine (III). The
tertiary amine (II) obtained above (1.9 g; 3.2 mmol) was
dissolved in 4 ml of anhydrous dichloromethane (DCM),
and 2 ml of neat trifluoroacetic acid (TFA) was added.
The reaction mixture was kept under stirring overnight
at room temperature. The TFA was removed by flushing
with nitrogen and the remaining residue was kept under
vacuum for 15 min. The resulting trifluoroacetate salt of
the title compound was dissolved in 25 ml of DCM, and
25 ml of aqueous 1 N NaOH was added. The resulting
biphasic mixture was stirred at room temperature for 2 h.
The organic layer was washed with water (3 25 ml),
dried over anhydrous sodium sulfate, filtered and the
solvent from the filtrate was evaporated under rotary
evaporator. Column chromatographic purification of the
residue (using 60–120 mesh size silica gel and 2–3%
methanol in chloroform, v/v, as the eluent) afforded 1.5 g
of the title compound (93% yield, Rf¼0.4 using 10%
methanolic chloroform, v/v, as the TLC developing
solvent).
1H NMR (200 MHz, CDCl3): d/ppm¼0.9 [t, 6H, CH3-
(CH2)12-]; 1.2–1.4 [m, 52H, -(CH2)13-]; 1.5 [m, 4H, N(-CH2-
CH2-)2]; 2.5 [m, 4H, N(CH2-CH2-)2]; 2.6 [t, 2H, -N(CH2-
CH2-NH2)]; 2.9 [t, 2H, -N(CH2-CH2-NH2)]; 3.5–3.7 [bm,
2H, NH2].
Np,Nim,di-butyloxycarbonyl-L-histidine (IV). A mix-
ture of N,N-dimethylformamide (2 ml), water (2.5 ml),
triethylamine (2.5 ml; 17.9 mmol) and L-histidine
(770 mg; 5 mmol) was taken in a 50 ml round-bottomed
flask and the mixture was cooled to 01C. Di-tert-butyl-
pyrocarbonate (2.5 ml; 10.9 mmol) was added dropwise
to this cold solution. The reaction mixture was stirred
at room temperature for 48 h and washed with
hexane (20 ml). The hexane layer was extracted with
saturated aqueous NaHCO3 (20 ml). The combined
aqueous extracts were acidified with solid potassium
hydrogen sulfate to pH 2 and extracted with EtoAc
(3 20 ml). The EtoAc extract was washed with water
(4 20 ml), dried with anhydrous sodium sulfate, fil-
tered and the filtrate concentrated on a rotary evaporator
to give 1.25 g of the title compound as a white gummy
solid (71% yield).
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Figure 4 Transfection efficiency of Chol/lipid 1 into HeLa and HepG2
cells. The cells were transfected with 2.5 mg pCMVLuc complexed with
Chol/lipid 1 (lipid molar ratio of 2:1). The luciferase activity was measured
upon 24 h culture. DC-Chol/DOPE was used at a lipid molar ratio of 3:2.
The transfection values shown are average of three independent
experiments.
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1H NMR (CDCl3, 200 MHz): d/ppm¼1.4–1.5 [s, 18H, -
CO-O-(CH3)3]; 3.0 [dd, 2H, -CH2-CH(NHBoc)COOH]; 4.1
[m, 1H, -CH(NHBoc)COOH]; 6.1 [s, 1H, -NH-CO-O-
(CH3)3]; 6.9 [s, 1H, -NBoc-CH¼C-]; 7.7 [s, 1H, -NBoc-
CH¼N-].
Np,Nim,di-butyloxycarbonyl-L-histidine(N,N-di-n-hexa-
decylamine)ethylamide (V). A mixture of Nim,Np,Di-
Boc-L-histidine (0.68 g; 1.9 mmol), dicyclohexylcarbodii-
mide (0.41 g; 2 mmol), N-hydroxysuccinimide (0.271 g;
2.3 mmol) was dissolved in 8 ml of dry N,N-dimethyl-
formamide and stirred for 1 h. N-2-aminoethyl-N,N-di-n-
hexadecylamine (1 g; 2 mmol) dissolved in 2 ml of dry
DCM was added slowly to the mixture at 01C and stirred
for 24 h. In total, 50 ml of DCM was added to the reaction
mixture, and the mixture was washed with water
(3 100 ml) and dried with anhydrous sodium sulfate.
Silica gel column chromatography (using 60–120 mesh
size silica and 0.5–1% methanol in chloroform, v/v, as
the eluent) of the residue afforded 1.1 g of pure coupled
product (yield¼66%, Rf¼0.6 using 5% methanolic chloro-
form, v/v, as the TLC developing solvent).
1H NMR (CDCl3, 200 MHz): d/ppm¼0.9 [t, 6H, CH3-
(CH2)13-]; 1.2–1.3 [m, 52H, CH3-(CH2)13]; 1.4–1.6 [2s, 18H,
-CO-O-(CH3)3]; 2.5–2.6 [m, 6H, -N-CH2-(CH2)14-CH3; -N-
CH2-CH2-NH-CO-]; 2.9–3.0 [2 dd, 2H, -CH2-CH-NH-CO-
]; 3.3 [m, 2H, -CH2-CH2-NH-CO-]; 4.4 [m, 1H, -CH
(NHBoc)-CO-]; 6.1 [s, 1H, -NH-CO-O-(CH3)3]; 7.0 [s, 1H,
N-CH¼C-]; 8.0 [s, 1H, N-CH¼N-]:
fast atom bombardment mass spectrometry FABMS: m/z:
846 (36%).
L-histidine-(N,N-di-n-hexadecylamine)ethylamide
(lipid 1). Compound V (0.1 g; 0.12 mmol) was dis-
solved in 1 ml of 2 N HCl in dioxane and the solution
was kept under stirring at room temperature overnight.
The solvent was removed with nitrogen flush and the
residue was kept under vacuum for 1 h. Silica gel column
chromatography (using 60–120 mesh size silica and 10–
15% methanolic chloroform, v/v, as the eluent) of the
dried residue afforded 40 mg of pure title compound
(53% yield).
1H NMR (CDCl3, 200 MHz): d/ppm¼0.9 [t, 6H, CH3-
(CH2)13-]; 1.2–1.3 [m, 52H, CH3-(CH2)13-]; 1.6–1.7 [m, 4H,
-CH2-CH2-N+-]; 3.0 [m, 5H, -CH2CH(NH3+)CO-]; 3.3 [m,
4H, -N+(CH2-(CH2-)14-CH3]; 3.5 [m, 2H, -N+-CH2-CH2-
NH-CO]; 3.7 [m, 2H, -N+-CH2-CH2-NH-CO-]; 4.3 [m, 1H,
-CH(NH3+)CO-]; 7.2 [s, 1H, -N-CH¼C-], 8.3 [s, 1H, -N-
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Figure 5 Comparative transfection efficiencies of Chol/lipid 1 and Chol/lipid 2. Cells were transfected with 2.5 mg pCMVLuc (a, b and c) or pT7Luc (d)
complexed with the liposomes. The luciferase activity was measured upon 24 h culture. The transfection efficiency is expressed as the percentage relative to
Chol/lipid 1 (lipid molar ratio of 2:1). The transfection values shown are average of three independent experiments.
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CH¼N-]; 9.3 [s, 1H, -NH-CO-].
FABMS: m/z: 647 (40%).
Np,Nim,di-butyloxycarbonyl-L-histidine(N,N-di-n-hexa-
decylamine,N-methyl)ethylamide (VI). Compound V
(1 g, 12 mmol) was dissolved in 3 ml DCM, and 2 ml
methyl iodide was added. The solution was stirred for
1 h, solvent removed on rotary evaporator and silica gel
column chromatography (using 60–120 mesh size silica
and 2% methanolic chloroform, v/v, as the eluent) of the
residue afforded 0.42 g of the title compound (35% yield).
1H NMR(CDCl3, 200 MHz): d/ppm¼0.9 [t, 6H, CH3-
(CH2)13-]; 1.2–1.3 [m, 52H, CH3-(CH2)13-]; 1.4–1.6 [2s,
18H, CO-O-C(CH3)3]; 1.6–1.7 [m, 4H, -CH2-CH2-N+-]; 3.0
[m, 2H, -CH2-CH(NHBoc)CO-]; 3.2 [S, 3H, CH3-N+-]; 3.4
[m, 4H,-N+-CH2-(CH2)14-CH3]; 3.6–3.7 [bm, 4H, -N+-CH2-
CH2-NHCO-]; 4.3 [m, 1H, -CH(NHBoc)CO-]; 6.0 [s, 1H, -
NH-CO-O-(CH3)3]; 7.2 [s, 1H, -N-CH¼C-]; 8.0 [s, 1H, N-
CH¼N-]; 8.5 [s, 1H, - CH2-NH-CO-].
FABMS: m/z: 861 (40%).
L-histidine(N,N-di-n-hexadecylamine, N-methyl)ethyla-
mide (lipid 2). Compound VI (0.4 g, 0.46 mmol) was
dissolved in 2 ml of 2 N HCl in dioxane and the solution
was kept under stirring for 24 h. The solvent was
removed with nitrogen flush and the residue was kept
under vacuum for an additional 1 h. Silica gel column
chromatography (using 60–120 mesh size silica and 10–
15% methanolic chloroform, v/v, as the eluent) followed
by chloride ion-exchange chromatography (using Am-
berlyst-A 26 chloride ion-exchange resin) of the dried
residue afforded 90 mg of pure title compound (29%
yield).
1H NMR (CDCl3, 200 MHz): d/ppm¼0.9 [s, 6H, CH3-
(CH2)13-]; 1.2–1.3 [m, 52H, CH3-(CH2)13-]; 1.6–1.7 [m, 4H,
CH3-(CH2)13-CH2-CH2-N+-]; 3.0 [2 dd, 2H, -CH2-
CH(NH3+)CO-]; 3.2 [S, 3H, CH3-N+-CH2-CH2-]; 3.4–3.7
[m, 8H, (CH3-(CH2)14-CH2)2-N+(CH3)-CH2-CH2-NHCO-
]; 4.1 [m, 1H, -CH(NH3+)CO-]; 6.9 [s, 1H, -N-CH¼C-]; 7.7
[s, 1H, -N-CH¼N-]; 7.4 [s, 1H, -CH2-CH2-NH-CO-].
FABMS: m/z: 661 (80%).
x potential and size measurements
The charge and the size of liposomes and lipoplexes
were measured by electrophoretic mobility and quasi-
elastic laser light scattering (QELS), respectively, using
Zeta Sizer 3000 (Malvern Instruments, Orsay, France).
The size was measured in 10 mM Hepes buffer, pH 7.4,
10 times with a sample refractive index of 1.59 and a
viscosity of 0.89. The system was calibrated using the
20075 nm polystyrene polymer (Duke Scientific Corps
Palo Alto, CA, USA). The diameter of liposomes and
lipoplexes was calculated by using the automatic mode.
The x potential was measured in 10 mM Hepes buffer, pH
7.4, with the following parameters: viscosity, 0.891 cP;
dielectric constant, 79; temperature, 251C; F(Ka), 1.50
(Smoluchowsky); maximum voltage of the current, 15 V.
The system was calibrated using DTS 5050 standard from
Malvern. Measurements were done 5 times with the zero
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Figure 6 The membrane fusion activity of Chol/lipid 1. Fusion versus pH. Fusion was induced by adding PC/NBD-PE/Rho-PE liposomes (0.01 mmol) to
Chol/lipid 1 (lipid molar ratio of 2:1) (0.4 mmol in 0.6 ml of 10 mM Hepes buffer at  pH 7.4, ’ pH 6.0, and m pH 5.0) directly in the cuvette. Insert:
Fusion versus the amount of Chol/lipid 1. Fusion was induced by adding PC/NBD-PE/Rho-PE liposomes (0.01 mmol) to various amounts of Chol/lipid 1
(lipid molar ratio of 2:1) (in 0.6 ml of 10 mM Hepes buffer, pH 7.4) directly in the cuvette. The fluorescence intensity of rhodamine was monitored at 301C.
The values shown are representative of three independent measurements.
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field correction. The x potential was calculated using the
Smoluchowsky approximation.
Cells and Cell Culture
Human hepatocarcinoma HepG2 cells (8055 HB, ATCC,
Rockville, MD, USA), human epithelial ovary carcinoma
HeLa cells (CCL21, ATCC), human carcinoma lung A549
cells (CCL185, ATCC) and human embryo kidney 293T7
cells25 were cultured in MEM containing 10% heat-
inactivated fetal bovine serium (Life Technologies, Cergy
Pontoise, France), 2 mM L-glutamine (Life Technologies),
100 U/ml penicillin (Life Technologies) and 100 U/ml
streptomycin (Life Technologies). 293T7 cells were
cultured in the presence of geneticin (400 mg/ml). Cells
were mycoplasma-free as evidenced by bisbenzimida-
zole (Hoechst 33258, Molecular Probes).32
Plasmids
pCMVLuc (pUT650, 5.15 kb, Cayla, Toulouse, France)
and pT7Luc (kindly given by Dr M Brisson) were
plasmid DNA encoding the firefly luciferase under the
control of the human cytomegalovirus and the bacter-
iophage T7 RNA polymerase promoter, respectively.
Supercoiled plasmid DNA was isolated by a standard
alkaline lysis method and purification was carried out
with the QIAGENs Plasmid Mega kit (QIAGEN,
Courtaboeuf, France).
Transfections
Two days prior to transfection, cells were seeded at
2 105 cells in 2 ml culture medium in a 12-wells plate.
At the time of the experiment, cell cultures were 80%
confluent and lipofections were performed as described
below. Liposomes were prepared by ethanol injection
method: 15 ml of an ethanol solution of the lipid mixture
– Chol/lipid1, Chol/lipid2 or DC-Chol/DOPE (DC-Chol
and DOPE from Sigma) – at 2.7 mM or 5.4 mM was
injected rapidly into 200 ml of 10 mM Hepes buffer, pH
7.4. After 15 min at room temperature, the liposomes
were mixed with the plasmid (5 mg in 20 ml of 10 mM
Hepes buffer, pH 7.4). After 15 min at room temperature,
the lipoplexes solution was completed at 1 ml with
serum-free medium and the NaCl concentration was
adjusted at 0.15 M with a 5 M NaCl solution. Before
incubation with 0.5 ml lipoplexes, cells were washed 2
times with serum-free culture medium. Cells were
incubated for 4 h at 371C, the medium was removed
and cells were cultured for 48 h at 371C in complete
culture medium without any additives.
LipofectAMINEt (Life Technologies) or Lipofectint
(Roche Diagnostic, Meylan, France), DOTAP (Roche
Diagnostic), FuGENEt6 (Roche Diagnostic) were used
according to the manufacturer’s procedure. Briefly, 25 ml
of Lipofectin or Lipofectamine was added to 100 ml of
OPTIMEM, left for 15 min at room temperature and then
mixed with DNA (2.5 mg in 100 ml OPTIMEM). After
15 min, the lipoplexes solution was completed at 1 ml
with OPTIMEM. DOTAP liposomes were made by
adding 30 ml of DOTAP in 100 ml of 20 mM Hepes buffer,
pH 7.4. After 15 min at room temperature, liposomes
were mixed with DNA (5 mg in 100 ml of 20 mM Hepes
buffer, pH 7.4). Upon 15 min complexation at room
temperature, the lipoplexes solution was completed at
2 ml with serum-free MEM. FuGENEt6 liposomes were
prepared by adding 6 ml of FuGENEt6 in 100 ml of
DMEM. After 15 min at room temperature, the liposomes
were mixed with DNA (2.5 mg in 100 ml DMEM). Then,
the lipoplexes solution was completed at 1 ml with
serum-free DMEM. The cell transfection procedure using
these reagents was similar as described above.
Luciferase assay
Luciferase gene expression was measured by monitoring
the luminescence activity according to De Wet et al.33 The
medium was discarded and cells were washed 3 times
with PBS. The homogenization buffer (200 ml of 8 mM
MgCl2, 1 mM dithiothreitol, 1 mM ethylenetetra acetic
acid, 1% Triton X-100, 15% glycerol, 25 mM Tris-phos-
phate buffer, pH 7.8) was added into each well and tissue
culture plates were kept for 15 min at 201C. The solution
was recovered and spun down (5 min at 800 g). A total,
95 ml of a 2 mM ATP solution in the homogenization
buffer without Triton X-100 was added to 60 ml super-
natant and the solution was shaken with a vortex. The
luminescence was recorded for 4 s in a Lumat LB 9501
luminometer (Berthold, Wildbach, Germany) upon addi-
tion of 150 ml of a 167 mM luciferin solution in water.
Measurements were done in duplicate. The number of
relative light units (RLU) of 1 pg/ml of luciferase was
2000 under these assay conditions. The data shown
correspond to the number of RLU per mg proteins.
Proteins were determined on each sample using the
modified bicinchoninic acid (BCA) colorimetric assay.34,35
Membrane fusion
The membrane fusion activity of Chol/lipid 1 liposomes
was measured with the FRET assay as previously
described.30 NBD-PE (Molecular Probes, Eugene, OR,
USA) and Rho-PE (Molecular Probes) were used as
donor and acceptor fluorescent lipids, respectively. PC
(1.14 mg; 1.8 mmol in chloroform) (Sigma), NBD-PE
(0.05 mg; 0.052 mmol in ethanol) and Rho-PE (0.14 mg;
0.096 mmol in ethanol) were mixed and dried under
reduced pressure. The dried lipid films were hydrated
overnight at 41C in 4 ml of 10 mM Hepes buffer, pH 7.4.
The suspension was vigorously vortexed for 2–5 min at
room temperature and sonicated for 15 min in cold bath
sonicator at 35 kHz (Bioblock Scientific, Strasbourg,
France). Fusion was induced by adding PC/NBD-PE/
Rho-PE liposomes (0.01 mmol) to Chol/lipid 1 (lipid
molar ratio 2:1) liposomes (0.4 mmol in 0.6 ml of 10 mM
Hepes buffer, pH 7.4) directly in the cuvette. The
fluorescence intensity of rhodamine was monitored with
a spectrofluorometer (Jobin-Yvon Fluoromax-2). The
excitation was at 465 nm and emissions were at 530
and 580 nm for NDB and Rho, respectively. All experi-
ments were done at 301C. Fusion (100%) was determined
from the rhodamine fluorescence intensity of PC/NBD-
PE/Rho-PE liposomes in the presence of 0.1% Triton
X100.
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